Sign Up | Log In | What is SocialPicks?

Vasogen Inc. (VSGN) Trade Now » Rate VSGN - Discuss VSGN - Add to Watch List

Sector: Healthcare > Industry: Medical Equipment & Supplies

This is a micro-cap stock and may be a target of manipulation. Always do your research!

SocialPicks Sentiment:

** v.s. other stocks

This Quarter's Sentiment:

All:

100.0%

Top:

100.0%

Rate VSGN:

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

VSGN: Bull or Bear?

From: SocialPicks | Blogsphere | All

SocialPicks Community

Vasogen News: Just Read The Second Paragraph VSGN

-88.67%
in 867 days

Vasogen (NASDAQ:VSGN) announces Q2 earnings. One reads the press release and reads and reads. Most corporations lead with the bottom line. Vasogen trumpets the fact that they still have cash available. They eventually get to the bottom line which does have losses. The company is unintentionally signalling that balance sheet considerations outweigh operations such as developing new drugs and therapies. But they want you to believe that they are able to survive and reach the next level.

In the same press release they echo some previous comments that they made on June 27 about meetings ...

Continue reading »

By George Gutowski (-38.39% risk: aggressive) 07/13/07

Comment

VSGN is a buy VSGN

55%

-93.71%
in 989 days

Rodman & Renshaw, LLC Announces Investment Opinion: Rodman & Renshaw, LLC Initiates Coverage of Vasogen Inc. With A Market Outperform Rating <o:p> </o:p>

2007-02-27 08:40 ET - News Release

Analyst Sets 12 Month Target Price of $3

NEW YORK -- (Business Wire)

Rodman & Renshaw, LLC initiated research coverage of Vasogen Inc. (NASD: VSGN) with a Market Outperform Rating and a 12-month price target $3. Navdeep Jaikaria, Ph.D., Senior Biotechnology Analyst, issued the report.

About Rodman & Renshaw, LLC

<>Rodman & Renshaw is a privately held, full-service invest...

Continue reading »

By Moneycrackerlee (-1.52% risk: aggressive) 03/13/07

Comment

VSGN is a buy VSGN

55%

-93.71%
in 989 days

Rodman & Renshaw, LLC Announces Investment Opinion: Rodman & Renshaw, LLC Initiates Coverage of Vasogen Inc. With A Market Outperform Rating <o:p> </o:p>

2007-02-27 08:40 ET - News Release

Analyst Sets 12 Month Target Price of $3

NEW YORK -- (Business Wire)

About Rodman & Renshaw, LLC

<>Rodman & Renshaw is a privately held, full-service invest...

Continue reading »

By Moneycrackerlee (-1.52% risk: aggressive) 03/13/07

Comment

VSGN is a buy VSGN

55%

-93.71%
in 989 days

Rodman & Renshaw, LLC Announces Investment Opinion: Rodman & Renshaw, LLC Initiates Coverage of Vasogen Inc. With A Market Outperform Rating <o:p> </o:p>

2007-02-27 08:40 ET - News Release

Analyst Sets 12 Month Target Price of $3

NEW YORK -- (Business Wire)

About Rodman & Renshaw, LLC

<>Rodman & Renshaw is a privately held, full-service invest...

Continue reading »

By Moneycrackerlee (-1.52% risk: aggressive) 03/13/07

Comment

VSGN is a buy VSGN

55%

-93.71%
in 989 days

Rodman & Renshaw, LLC Announces Investment Opinion: Rodman & Renshaw, LLC Initiates Coverage of Vasogen Inc. With A Market Outperform Rating <o:p> </o:p>

2007-02-27 08:40 ET - News Release

Analyst Sets 12 Month Target Price of $3

NEW YORK -- (Business Wire)

About Rodman & Renshaw, LLC

<>Rodman & Renshaw is a privately held, full-service invest...

Continue reading »

By Moneycrackerlee (-1.52% risk: aggressive) 03/13/07

Comment

« previous
1
2
next »

From the Blogosphere

« previous
« next

ROCK-STAR INVESTORS

Rank	Name	Sharpe Ratio	Avg Return	Followers
1	noshoes	21.10	+34.25%	381
2	Gerald Greene	18.14	+72.34%	210
3	stockmarketfunding.com	17.66	+25.65%	55
4	akiralegrand	13.47	+14.32%	61
5	anup2104	12.13	+76.91%	39

... more »

POPULAR STOCKS

Symbol	Company Name	Sentiment
RIMM	Research in Motion Ltd
V	Visa Inc
BAC	Bank of America Corp
RIO	Companhia Vale Do Rio Doce
WFC	Wells Fargo & Company
FNM	Fannie Mae

... more »

TODAY'S HEADLINES

LDK Solar's Growth Potential Offset by Gross Margin Pressure
by Paul Cheung (Zacks.com) about LDK

Cisco Systems Still a Wait and See
by Thomas Catino (Ant & Sons) about CSCO

The Merrill Lynch Diet: Starving Shareholders
by Zack Miller (BloggingStocks) about MER

Until Housing Improves, Don't Expect Stocks to Rebound
by J.D. Steinhilber (Agile Investing) about SPY

Google Blows Q2: Multiple Compression to Continue
by Henry Blodget about GOOG

... more »

TODAY'S TOP PICKS

CLDA		BioMed Research Reports: Clinical Data (NASDAQ: CLDA), Lpath (OTC: ... by Mike Havrilla
PARD		Biotech Stocks - Beware of The Covered Call Trap by Ivan Mutaftchiev
PBIO		Under the Radar Healthcare Stocks: Protox, Pressure BioSciences, Un... by Mike Havrilla
ISIS		ISIS - Last Tuesday's Drop Presents a Nice Buy Opportunity by Ivan Mutaftchiev
ABIO		BioMed News Bytes: Transcept, ProUroCare, SciClone, ABIO by Mike Havrilla

... more »

StreetInsider.com on VSGN

Visit streetinsider.com

Discussion Wall

+ Add

Be the first to start a discussion and earn 2 points.

... more »

More Resources

About Vasogen Inc. - Answers.com

Historical Prices - Yahoo

Message Boards - BoardCentral.com

More Info: Yahoo | Google | Reuters

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.